Free Trial

Innate Pharma (IPHYF) SEC Filings & 10K Form

Innate Pharma logo
$1.31 0.00 (0.00%)
As of 08/8/2025

Recent Innate Pharma SEC Filings

DateFilerForm TypeView
08/04/2025
5:49 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/29/2025
5:24 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/07/2025
5:03 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/17/2025
5:05 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/13/2025
5:00 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/30/2025
7:31 AM
Innate Pharma (Subject)
Innate Pharma SA (Subject)
NOVO NORDISK A S (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/27/2025
5:03 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/23/2025
5:11 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/23/2025
5:17 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/19/2025
5:03 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/15/2025
5:00 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/13/2025
5:03 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/12/2025
5:03 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/06/2025
5:01 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/30/2025
10:31 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/30/2025
8:01 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
04/29/2025
5:48 PM
Innate Pharma (Subject)
Innate Pharma SA (Subject)
Sanofi (Filed by)
Sanofi (Filed by)
Form SCHEDULE 13G/A
04/29/2025
2:02 PM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/28/2025
5:00 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/24/2025
5:03 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/23/2025
7:28 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/16/2025
5:05 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/16/2025
5:07 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/03/2025
5:00 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/27/2025
6:01 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/26/2025
6:07 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/25/2025
6:23 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/20/2025
6:24 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/27/2025
5:01 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/18/2025
5:16 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/27/2025
6:57 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/21/2025
5:00 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/16/2025
7:16 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/10/2025
5:01 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/20/2024
6:03 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/09/2024
5:04 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/06/2024
5:00 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/03/2024
5:03 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/20/2024
5:02 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/19/2024
5:01 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/13/2024
5:00 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer? (Ad)

Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.

We recently interviewed Rickards to get the full story and understand how everyday Americans can pre
11/08/2024
5:00 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/07/2024
5:00 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/29/2024
6:03 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/15/2024
5:11 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/30/2024
5:15 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/23/2024
5:03 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/12/2024
5:15 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/12/2024
5:07 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/11/2024
3:00 PM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
09/09/2024
5:13 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/05/2024
5:10 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/04/2024
5:11 AM
Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (OTCMKTS:IPHYF) was last updated on 8/10/2025 by MarketBeat.com Staff
From Our Partners